Significant alterations were observed in lipid levels and other skin biomarkers for infants who developed atopic dermatitis (AD) vs controls, with phytosphingosine associated with the highest AD prediction accuracy.
Significant alterations were observed in lipid levels and other skin biomarkers for infants who later developed atopic dermatitis (AD) vs those who did not, according to study findings published recently in Current Medical Research and Opinion.
In examining risk factors for the development of pediatric AD, parental history of atopic disease and occurrence of common filaggrin gene (FLG) mutations have been cited. Moreover, patients with AD have important alterations in extra-cellular lipid composition, noted researchers, such as shorter chain lengths of fatty acids (FAs) in ceramides and of free FAs, which further reduce the performance of the skin barrier.
“Several hundreds of ceramide species can be identified, which differ in the type of sphingoid base (SB) and FA chain. There are 4 main SBs, dihydrosphingosine (DS), sphingosine (S), 6-hydroxy-sphingosine (H), and phytosphingosine (P), which in combination with varying FA chains give rise to 12 main ceramide (CER) classes,” they explained.
“Identification of predictive biomarkers is important to guide future prevention efforts and ultimately halt the atopic march…The role of the chain length variability of the SB in AD has not been investigated.”
The study authors conducted a nested case-control study of the prospective Copenhagen Baby Skin birth cohort to determine whether selected skin biomarkers, derived via stratum corneum tape strips in infants with clinically normal skin at 2 months of age, were different in children who develop AD in the first year of life vs those who do not.
Natural moisturizing factor (NMF), corneocyte surface protrusions, cytokines, free SBs of different chain lengths, and their ceramides were analyzed from tape strips collected at 2 months of age before onset of AD using liquid chromatography, atomic force microscopy, multiplex immunoassay, and liquid chromatography mass spectrometry, respectively.
Of the 300 children followed prospectively from birth until 2 years of age, 44 random children with onset of AD in the first year of life were matched on sex and season of birth with 44 children who did not develop AD.
Among children who developed AD, 66% had parental history of atopy compared with 52% of children who did not develop AD (P = .4). The median age of AD onset was 4.0 months, and the median Eczema Area and Severity Index (EASI) score was 4.2.
Between the 2 cohorts, significant alterations were observed for 4 lipid markers, with P levels shown to be significantly lower in children who developed AD vs children who did not (median 240 vs 540 pmol/mg; P < .001).
The 2 groups of children also differed in the relative amounts of SB of different chain lengths (C17, C18, and C20), and thymus- and activation-regulated chemokine (TARC/CCL17) was slightly higher in those who developed the skin disease.
P was indicated to have the highest prediction accuracy among the biomarkers (75.6%), whereas the combination of 5 lipid ratios (DS, S, P, H, CER) gave an accuracy of 89.4%. NMF and corneocyte surface texture ratios were conversely similar for both cohorts.
The researchers acknowledged that since no predictive studies have been done for other skin diseases (eg, psoriasis), findings may not be specific to AD. The selection of biomarkers previously identified in clinical studies was also noted as a limitation, as some important biomarkers may have been overlooked.
Reference
Rinnov MR, Hailing AS, Gerner T, et al. Skin biomarkers predict development of atopic dermatitis in infancy. Allergy. Published online September 16, 2022. doi:10.1111/all.15518
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More